

Cognitive-Communication Disorders of MCI and Dementia

**Definition, Assessment,
and Clinical Management**

Third Edition

Cognitive-Communication Disorders of MCI and Dementia

Definition, Assessment,
and Clinical Management

Third Edition

Kathryn Bayles, PhD, CCC-SLP
Kimberly McCullough, PhD, CCC-SLP
Cheryl Tomoeda, MS, CCC-SLP





5521 Ruffin Road
San Diego, CA 92123

e-mail: information@pluralpublishing.com
Web site: <http://www.pluralpublishing.com>

Copyright © 2020 by Plural Publishing, Inc.

Typeset in 10/12 Palatino by Achorn International
Printed in the United States of America by McNaughton & Gunn, Inc.

All rights, including that of translation, reserved. No part of this publication may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, recording, or otherwise, including photocopying, recording, taping, Web distribution, or information storage and retrieval systems without the prior written consent of the publisher.

For permission to use material from this text, contact us by
Telephone: (866) 758-7251
Fax: (888) 758-7255
e-mail: permissions@pluralpublishing.com

Every attempt has been made to contact the copyright holders for material originally printed in another source. If any have been inadvertently overlooked, the publishers will gladly make the necessary arrangements at the first opportunity.

Library of Congress Cataloging-in-Publication Data:

Names: Bayles, Kathryn A., 1942- author. | McCullough, Kimberly (Speech-language pathologist), author. | Tomoeda, Cheryl K., author.

Title: Cognitive-communication disorders of MCI and dementia : definition, assessment, and clinical management / Kathryn Bayles, Kimberly McCullough, Cheryl Tomoeda.

Other titles: Cognitive-communication disorders of dementia

Description: Third edition. | San Diego, CA : Plural Publishing, [2020] | Preceded by Cognitive-communication disorders of dementia / Kathryn A. Bayles and Cheryl K. Tomoeda. Second edition. 2014. | Includes bibliographical references and index.

Identifiers: LCCN 2018028636 | ISBN 9781635500608 (alk. paper) | ISBN 1635500605 (alk. paper)

Subjects: | MESH: Cognitive Dysfunction—diagnosis | Dementia—diagnosis | Communication Disorders—etiology | Dementia—complications | Communication Disorders—diagnosis | Communication Disorders—therapy

Classification: LCC RC521 | NLM WM 220 | DDC 616.8/3—dc23

LC record available at <https://lcn.loc.gov/2018028636>

Contents

<i>Preface</i>	<i>xiii</i>
<i>Acknowledgments</i>	<i>xv</i>
1 Speech-Language Pathology, Mild Cognitive Impairment, and Dementia	1
Introduction	1
Communication Defined	2
Rationale for Therapy	2
Neuroplasticity	3
Memory Systems and Their Selective Vulnerability to Disease	3
Cognitive Reserve	5
Summary of Important Points	6
References	7
2 Cognition, Memory, and Communication	11
Cognition and Memory	11
The “Company of Cognition”	11
Memory Defined	12
Sensory Memory	12
Working Memory	13
Long-Term Memory	14
Relation of Cognition and Memory to Communication	19
Production of Linguistic Information	19
Comprehension of Linguistic Information	20
Summary of Important Points	20
References	21
3 MCI: Mild Cognitive Impairment a.k.a. Mild Neurocognitive Disorder	25
Introduction	25
Prevalence of MCI	25
Diagnostic Criteria for MCI	26
Risk and Protective Factors	26
Causes and Clinical Presentations of MCI	27
Neuropsychological Deficits Associated with MCI	27
Language Performance Deficits	28
Conversion to Dementia	32
Conclusion	33
Summary of Important Points	33
References	33

4	Alzheimer's Dementia	39
	Alzheimer's Disease (AD) Introduction	39
	Diagnostic Criteria for AD	39
	Risk Factors for AD	42
	Age	42
	Family History of AD	42
	Education	44
	History of Head Trauma	45
	Loneliness	45
	Gender	45
	Maternal Age	45
	Apolipoprotein E4 Allele	46
	Chronic Lack of Sleep	46
	Mild Cognitive Impairment	46
	Predictors of Disease Progression	46
	Protective Factors	46
	Effects of AD on Cognitive and Communicative Functions	46
	Early Stage	47
	Middle Stage	50
	Late Stage	52
	Summary of Important Points	53
	References	54
5	Dementia and Down Syndrome	61
	Introduction	61
	Common Features of People with DS	61
	Risk of Developing Alzheimer's Disease	61
	Prevalence of Dementia in DS	62
	Diagnosing Dementia in Individuals with DS	63
	A Study of the Cognitive-Communication Profiles of DS Adults with and without Dementia	64
	Language and Communication Skills in Adults with DS	64
	Premorbid Language	64
	Language Change in Dementia	65
	Cognitive and Behavioral Measures Appropriate for Individuals with DS	65
	Summary of Important Points	67
	References	67
6	Vascular Dementia	71
	Introduction	71
	Neuropathology	71
	Diagnostic Criteria	73
	Diagnosing Vascular Cognitive Impairment	73

Risk Factors for VaD	73
Aging	73
Hypertension	73
Family History	74
Ethnicity and Gender	74
Diabetes Mellitus (Type 2)	74
Lifestyle	74
Vascular Pathology May Be a Trigger for Alzheimer's Dementia	75
Comparison of Effects of Cortical and Subcortical Pathologies on	
Cognition and Communicative Function	75
Cortical Pathologies	75
Subcortical Pathologies	76
VCI Compared with AD	76
Observations from Course-of-Disease Studies	76
Summary: Effects of VCI on Cognitive and Communicative Functioning	77
Conclusion	77
Summary of Important Points	77
References	78
7 Parkinson's Disease and Dementia	83
Parkinsonism and Parkinson's Disease (PD)	83
Incidence and Prevalence	83
Symptoms of PD: Motor, Affective, Cognitive	83
Neuropathology of PD	85
Risk Factors	85
Diagnostic Criteria for PD	86
Cognition: Continuum from Normal to Dementia	86
Diagnostic Criteria PD-MCI	86
Diagnostic Criteria for Parkinson's Disease with Dementia (PDD)	87
Prevalence of PDD	87
Nature of Cognitive Impairment	87
Attention/Executive Function	87
Memory	88
Visuoperceptual/Visuospatial Function Deficits	89
Communicative Function of PD Patients without and with Dementia	89
A Study of Communicative Function in Demented PD Patients	90
Individuals with PD and Dementia Compared with Individuals	
with AD on the ABCD	91
Discourse Sample of PD Patient with Dementia	91
Relation of PDD, Dementia with Lewy Bodies, and AD	92
Summary of Important Points	92
References	93

8	Dementia and Lewy Body Disease	99
	Lewy Body Disease	99
	Diagnostic Criteria and Symptomatology	100
	Consortium Consensus Criteria for Diagnosis of Dementia	102
	Caregiver Report of Early Symptoms	102
	LBD Risk Factors	102
	Effects of LBD on Cognition	103
	Executive Function and Attention	103
	Visuoperceptual and Spatial Functions	103
	Memory	104
	Language and Communicative Function	104
	A Case of Pure LBD	105
	Summary of Changes in Communicative Functioning	106
	Cognitive Profile of LBD Compared with AD	106
	Cognitive Profile of LBD Compared with PDD	106
	Summary of Important Points	107
	References	107
9	Dementia and Huntington's Disease	113
	Overview and Genetics of Huntington's Disease	113
	Neuropathology of HD	114
	Symptomatology	114
	Affect and Motor Symptoms	114
	Effects of HD on Speech	114
	Effects on Cognition	115
	Language	116
	Dysphagia Is Also a Concern	118
	Cognition and Communication	118
	Summary of Important Points	119
	References	119
10	Frontotemporal Dementia	123
	Introduction	123
	Diagnosis of Frontotemporal Dementia (FTD)	124
	Behavioral Presentation	124
	Behavioral Variant Frontotemporal Dementia (bvFTD)	124
	Language Presentation of FTD: Primary Progressive Aphasia	127
	Variants of PPA	127
	Differentiating the Behavioral Variant of FTD from the Primary	
	Progressive Aphasia Variants	131
	Amyotrophic Lateral Sclerosis and FTD	131
	Effects of ALS-FTD on Language	132
	Summary of Important Points	132
	References	133

Clinical Management Guide: Assessments and Interventions for Cognitive-Communication Disorders of Dementia

I	Assessment	141
	Introduction	141
	Assessment Procedures that Produce Valid and Reliable Data	141
	Prior to Testing	141
	Be Alert to Depression	143
	Be Alert to Drug Effects on Performance	143
	Know the Criteria for Diagnosing MCI and Dementia	144
	Severity of Cognitive Impairment Affects Test Selection	145
	Tests for Diagnosing MCI and Dementia	146
	Arizona Battery for Communication Disorders of Dementia (ABCD-1) aka Arizona Battery for Cognitive-Communicative Disorders (ABCD-2)	146
	ABCD-2 Subtests Most Sensitive to Mild AD	153
	Functional Linguistic Communication Inventory (FLCI) for Moderately and Severely Demented Individuals	153
	Many Other Tests Are Available for Diagnosing MCI and Dementia	154
	Broad-Based Assessments	155
	Short Screening Tests	157
	What About Aphasia Test Batteries?	157
	ADAS-COG: Widely Used in Drug Trials	158
	Differentiating the Types of Dementia	158
	Differentiating MCI and Mild Dementia from Delirium and Depression	158
	Differentiating Frontotemporal Dementias (FTD)	159
	Differentiating Primary Progressive Aphasia (PPA) and Mild AD	161
	An Assessment for Differentiating Semantic Dementia: The Cambridge Semantic Memory Test	162
	Differentiating AD from Vascular Dementia	163
	Differentiating Mild AD from Dementia with Lewy Bodies (DLB) and Parkinson’s Disease with Dementia (PDD)	165
	Summary of Important Points	166
II	Cognitive Intervention	169
	A Treatment Model for Successful Clinical Intervention	169
	Cognitive Intervention for Mild Cognitive Impairment (MCI)	169
	Cognitive Reserve is “ <i>Neuroprotective</i> ”	170
	Cognitive Intervention Strengthens Cognitive Reserve	170
	Make Treatment Person Centered	171
	Suggestions for How To Make Therapy Person Centered	172
	Target Skills and Behaviors that Have the Potential to Improve	172
	Provide Individual and Group Therapy	172
	Provide Training of Strategies that Can Improve Function	173

Use Repetition and Repeated Retrieval to Create and Strengthen New Learning	174
Computer-Based Training	175
Include Neuro-Proactive Education for Clients About Physical, Mental, and Social Health	176
Provide Opportunities to Support Communicative Engagement and Socialization	177
Ensure that Duration of Treatment Is Sufficient to Strengthen Skills and Create Learning	178
Use Objective and Subjective Measures of Skill Strength and Learning	179
Looking Forward	180

III Treatment: Direct Interventions for Individuals with Mild Cognitive Impairment and Dementia	181
Introduction	181
Clinical Strategies Supported by Neuroscience	181
Strategy: Provide Stimulation Related to Client’s Needs	181
Strategy: Personalize Tasks by Giving Clients Choices	182
Strategy: Involve Multiple Modalities	182
Strategy: Avoid Having Clients Multitask	184
Strategy: Engage Clients through Self-Generation	185
Strategy: Control Task Complexity	185
Strategy: Work within Schemas to Increase Knowledge and Facilitate Retrieval	187
Strategy: Use Stimuli that Evoke Positive Emotion	188
Strategy: Use Reminiscence to Stimulate Recall, Engage Attention, and Elicit Emotion	188
Strategy: Design Stimulation to Reduce Errors	189
Strategy: Use Repetition to Produce Durable Memory	191
Repeated Retrieval: A Potent Form of Repetition that Profoundly Affects Learning	191
Spaced Retrieval: Retrieval of Information or Actions Over Increasingly Longer Intervals	192
Strategy: Elaborated Encoding Produces Stronger Memory	194
Strategy: Use Priming to Facilitate Memory and Increase Knowledge	194
Strategy: Use Reward to Sustain Attention, Increase Frequency of Desired Response, and Elicit Positive Emotion	196
Strategy: Provide Education About How Sleep, Diet, and Exercise Support Neuroplasticity and Cognition	196
Summary: Science and Clinical Practice	198

IV	Indirect Interventions for Individuals with Dementia	199
	Overview	199
	Linguistic Modifications	199
	Improving Language Comprehension	199
	Improving Language Production	202
	Environmental Modifications	205
	Facilitate Perception of Stimuli	205
	Vision and Aging	205
	Managing Problems with Vision to Facilitate Learning	206
	Color and Vision	207
	Hearing and Aging	208
	Facilitating Mood and Behavior	209
	Provide Something to Nurture	210
	Reduce Verbal Perseveration and Disruptions	210
	The Environment Should Promote Safety	211
	Technologies to Support Cognition and Communication	211
	Technologies to Support Memory	212
	Technologies to Support Engagement	212
	Technologies to Support Safety and Independence	213
	Support of Feeding	214
	Caregiver Education and Support	214
	Health Risks of Caregiving	215
	Gender and Caregiving	216
	Family Strife and Violence	216
	Factors that Influence Caregiver Burden and Stress	217
	Ethnic Minority Groups and Caregiver Burden	217
	Family Counseling	219
	Culture Matters in Counseling	219
	Emphasize What the Patient Can Do	220
	Caregiver Education and Training	221
V	Reimbursement and Care Planning for Persons with Dementia	223
	Introduction	223
	Federal Law Mandates Care	223
	Medicare's Comprehensive Assessment	223
	Minimum Data Set	224
	Care Area Assessment (CAA) Process	224
	Centers for Medicare and Medicaid Services	225
	Role of the SLP	225
	A Relevant Question	226
	Can SLPs Be Reimbursed for Cognitive Therapy?	226
	Medicare Review Threshold for Therapy Claims	227
	Using Test Performance to Develop Treatment Plans	227
	Planning Intervention	227

A Case-Based Example of a Restorative Care Plan	228
A Case-Based Example of a Maintenance Program	232
Documentation Is Critical	234
Evaluation and Plan of Care	234
Progress Notes	234
Treatment Encounter Notes	234
Documentation Pitfalls	235
Synopsis	235
<i>References for Clinical Guide</i>	237
<i>Index</i>	259

Preface

Since publication of the second edition of *Cognitive-Communication Disorders of Dementia*, a tsunami of dementia research has been published. More than ever, the focus is MCI, or mild cognitive impairment, typically a harbinger of a dementia producing disease. Historically, however, the term MCI was primarily associated with Alzheimer's disease, though scientists and clinicians recognized that all dementing diseases create subtle early cognitive impairments. This problem was remedied with the publication of the fifth edition of the *Diagnostic and Statistical Manual of Mental Disorders* (2013). The American Psychiatric Association introduced the term "minor neurocognitive disorder" to refer to mild cognitive impairments that are insufficient to be considered frank dementia, and they characterized dementia as a "major neurocognitive disorder." Nonetheless, clinicians and researchers still use the term MCI but with the understanding that it is associated with myriad diseases, and not just Alzheimer's.

Global interest in early identification of individuals with MCI is intense because drug and cognitive stimulation therapies, as well as lifestyle changes, show promise for delaying or preventing development of dementia. *Highly relevant to speech-language pathologists is the well-documented finding that language performance problems are among the earliest signs of MCI.* Moreover, the new recommendations for diagnosing MCI, also known as a "minor neurocognitive disorder," include the evaluation of language. As experts in language and commu-

nication science, speech-language pathologists are uniquely qualified to evaluate and treat the cognitive-based communication disorders of MCI and dementia. Thus, in this new edition, greater emphasis is given to the characteristics of MCI, its assessment, and clinical interventions.

The third edition opens with an overview of cognition and communication and why individuals with dementia have serious cognitive-communication disorders. This is followed by a rationale for building cognitive reserve in those with MCI and therapy for individuals with dementia. Chapter 2 provides an overview of cognition, memory, and communication, and how they are interrelated. Thereafter, clinicians and students in training will find up-to-date information about the characteristics of all major dementia-producing diseases and Down syndrome.

The last segment of the book is composed of the new Clinical Guide and is extensive. It begins with a discussion of the process of assessment and a review of reputable tests. Subsequent topics include:

- Cognitive stimulation programming for MCI
- Clinical techniques supported by the principles of neuroplasticity
- Indirect interventions that facilitate communication, quality of life and the safety of individuals with dementia, and caregiver counseling
- Care planning, goal setting, reimbursement, and required documentation

I

Speech-Language Pathology, Mild Cognitive Impairment, and Dementia

Introduction

Individuals with mild cognitive impairment (MCI) and dementia are the fastest-growing clinical population, nationally and globally. In fact, every 65 s someone in the United States develops Alzheimer's disease (AD), the leading cause of dementia (Alzheimer's Association, 2018; Ferri, Prince, Brayne, Brodaty, & Fratiglioni, 2005). Currently, 47 million individuals worldwide are believed to be living with dementia; however, by the year 2050, approximately 131.5 million people will have AD or another form of dementia (Alzheimer's Disease International, 2016). More than five million Americans live with AD, and that number may rise to 16 million by 2050. Characterized another way, one in 10 Americans 65 years or older has AD, two-thirds of whom are women. Individuals with dementia need care and an estimated 15 million Americans provide unpaid care. The cost of care in 2018 may exceed \$277 billion and a trillion dollars by 2050 (Alzheimer's Association, 2018).

Dementia-associated diseases, such as AD, can begin decades before they are clinically obvious and, once diagnosed, endure for many more years. Most patients are cared for at home by family, typically with serious financial, social, and emotional consequences

for all involved. Those patients and families who have the support of professionals have a higher quality of life (Gaugler, Roth, Haley, & Mittelman, 2008; Mittelman, Roth, Coon, & Haley, 2004) and speech-language pathologists (SLPs) are among the professionals who have an important role in the management of affected individuals. Language performance deficits occur early and worsen as the disease progresses. As experts in language and communication science and the evaluation and treatment of communication disorders, SLPs are uniquely qualified to diagnose and treat the cognitive-communication disorders associated with dementia-producing diseases. Additionally, SLPs provide counseling to professional and personal caregivers about how to best communicate with affected individuals.

The goal of this book is to provide practicing professionals and graduate students the knowledge needed to evaluate and treat individuals who have mild cognitive impairment (MCI), AD, or another type of dementia, as well as counsel professional and personal caregivers. Toward that end, the first order of business is answering the question, why do individuals with dementia have a communication disorder. To answer that question, we need to first define communication.

Communication Defined

Communication is the sharing of information by means of a symbol system. We call communication linguistic when words are used and nonlinguistic when other symbol systems are used, such as mathematical notation. To communicate, either linguistically or nonlinguistically, an individual must have an idea to share and a symbol system through which to express the idea. For example, symphony conductors communicate their ideas about tempo and loudness to orchestra members by moving a baton in prescribed ways. Football coaches communicate plays to players by hand signals. These are examples of nonlinguistic communication, and although nonlinguistic communication can be impaired as a consequence of a dementing disease, the focus of the SLP is impairment in linguistic communication. *Nonetheless, both nonlinguistic and linguistic communications are impaired in AD because both are cognitive processes for sharing and interpreting information and information processing is progressively disrupted.* Another distinction critical to characterizing the effects of dementia on communicative function is the difference between “speech” and “language.” For our purposes, the term “speech” refers to the motor production of sounds, and the term “language” refers to the symbol system by which sound is paired with meaning for a particular purpose. As previously noted, “linguistic communication” is the cognitive process of intentionally sharing ideas through language and in *dementia it is the ability to communicate that is typically most affected.*

“Meaningful” communication requires the production and comprehension of ideas. The act of speaking, in and of itself, does not constitute communication because that which is spoken may be structurally and semantically meaningless. Similarly, knowing the grammar of a language does not ensure the ability to communicate. Communication only occurs when words are structured in such a way that the listener comprehends the speaker’s idea. Having made this distinction, the question of why communication is affected in dementia can be answered. Communication is affected because the

pathophysiologic processes that disrupt multiple cognitive functions and produce dementia also disrupt information processing.

Clients with dementia are said to have a “cognitive-communication” problem because progressive deterioration of cognition interferes with communication. The fact is, *the production and comprehension of language cannot be separated from cognition.* Consider just the simple act of naming an object; for example, a parsnip. First, you must perceive the features of the parsnip. They must be matched to those in long-term memory for recognition to occur. Thereafter, you must form an intention to say the object’s name. The linguistic representations of objects are part of long-term lexical memory and must be retrieved and brought to consciousness. Perhaps you are uncertain about how a parsnip looks and therefore are unsure whether you are perceiving a turnip, parsnip, or rutabaga. If so, you have to decide whether to indicate your uncertainty. To articulate uncertainty about the object’s name or identity, a motor plan must be formed. Thus, the simple act of object naming requires perception, access to long-term memory, association, recognition, lexical retrieval, decision making, motor planning, and self-monitoring.

Persons with dementia have difficulty *producing* linguistic information because the information-processing capabilities of declarative and working memory systems are compromised, as is the case in AD (Hornberger, Bell, Graham, & Rogers, 2009; Rogers & Friedman, 2008), and in part because of progressive degradation of knowledge (Landin-Romero, Tan, Hodges & Kumfor, 2016), as is the case in semantic dementia. They have difficulty *comprehending* language because of deficits in the cognitive processes of perception, recognition, attention, and memory, as well as degradation of knowledge (Macdonald, Almor, Henderson, Kempler, & Andersen, 2001).

Rationale for Therapy

In the not too distant past, clinicians thought little could be done to improve the functioning

of individuals diagnosed with dementia. Early identification of those affected was not the priority it is today; however, as the number of dementia patients skyrocketed, interest in early detection and intervention also skyrocketed. Worldwide, researchers in neuroscience, as well as the behavioral and cognitive sciences, have focused on understanding dementia-associated diseases and their management. Research has revealed that individuals with AD experience subtle cognitive deficits years before the disease impairs their ability to live independently. When these individuals are identified, much can be done to prevent evolution to frank dementia or slow the course of the disease, among them pharmacologic interventions, lifestyle changes, and cognitive stimulation. Consider the following facts that comprise a rationale for intervention:

1. The human brain is plastic and many of the factors that advantage neuroplasticity are known.
2. Humans have multiple systems for learning and information representation that are not equally vulnerable to the pathology of the common dementia-producing diseases and spared systems can be strengthened to compensate for impairments.
3. Individuals with greater cognitive reserve exhibit dementia later than those with less.
4. Cognitive stimulation can produce learning and thus greater cognitive reserve in individuals with MCI.

In sum, SLPs now have evidence-based techniques that stimulate neuroplasticity and the building of cognitive reserve in individuals with MCI to delay conversion to dementia. Furthermore, they have evidence-based techniques for maximizing the functioning of those with clinically apparent dementia.

Neuroplasticity

Neuroplasticity is the lifelong ability of the brain to reorganize as a result of experience (Kleim &

Jones, 2008; Nudo & Bury, 2011). Learning is the byproduct of neuroplasticity. Intuitively, we know this to be true because we add to and refine our knowledge throughout life. Said another way, *neuroplasticity is experience-dependent and behavioral training is key to promoting brain reorganization after brain damage* (Raskin, 2011). Table 1–1 contains a list of empirically demonstrated factors that can be clinically manipulated to support neuroplasticity (Kleim & Jones, 2008; Kolb & Gibb, 2008; Shaffer, 2016). Not listed are hormones and drugs that also affect the capacity for recovery, but are not the province of SLPs.

Of particular significance to clinicians is the fact that the *type* of experience matters (the specificity principle). Learning can be negative or positive. An example of negative learning is the learned nonuse of a paretic limb. An example of positive learning is improvement in a language skill through language therapy.

To trigger neuroplasticity, sufficient stimulation is needed and the *type* of stimulation influences the way in which the brain reorganizes. For example, the presentation of an intensive program to incrementally challenge the auditory processing system can create structural changes in the network of cells that support auditory processing. Visual stimuli influence cell networks that support visual processing. A clinician who knows a client's profile of processing deficits and strengths can design a personalized stimulation program to influence brain response in a positive way. In the case of individuals with a neurodegenerative disease, such as Parkinson's disease or AD, the goal is to strengthen residual knowledge and skills, and if possible, build additional cognitive reserve.

Memory Systems and Their Selective Vulnerability to Disease

In Chapter 2, the various memory systems with their putative neuroanatomical substrates are described. Of significance to clinicians is how the neuropathology of the different dementia-associated diseases affects each disease. For example, as previously noted, the various memory

Table 1–1. Principles of Neuroplasticity

PRINCIPLE	DEFINITION
Attention	Learning requires attention. Attention is a function of stimulus relevance to the individual.
Specificity	Nature of stimulation dictates the nature of brain reorganization. For example, language stimulation produces changes in neuronal networks supporting language.
Use or Lose	Lack of use of knowledge or skills causes both to degrade.
Use and Improve	Use of knowledge and skills strengthens both.
Stimulation	Sensory and/or motor stimulation of sufficient intensity produce changes in brain.
Simultaneity	Concepts, words, actions that occur together become linked in nervous system.
Novelty/Challenge	New, enriching experience stimulates neurogenesis and increases gray matter volume and health of white matter.
Positive Emotion	Enhances mental performance.
Reward	Increases attention and frequency of desired behavior and creates positive emotion.
Constrain	Forced use stimulates the brain to reorganize.
Repetition	Repeated stimulation is essential for creation of long-term memory and skill building.
Intensity	Intense experience is needed for significant brain change.
Duration	The stimulation/experience must be of sufficient duration to create lasting change.
Interference	Brain reorganization in response to one experience can interfere with learning of a similar behavior.
Transference	Brain reorganization in response to one experience can enhance learning of a similar behavior.
Sleep	Regular sleep of 7–8 hours is necessary for consolidation of new information and skills.
Diet	High antioxidant, low fat, low sugar diet nourishes brain cells and reduces damaging free radicals.
Exercise	Exercise increases blood flow to the brain, increases gray matter volume, and energizes motor responses to improve speed of reaction.
Age	Plasticity is greater in childhood.
Time	Different forms of plasticity occur at different times.

Sources: Kleim & Jones (2008); Kolb & Gibb (2008); Shaffer (2016).

systems are not equally vulnerable to the effects of AD, especially early in the disease course. The neural structures that support working and declarative memory, particularly episodic memory, are affected early, whereas those supporting conditioning, motor procedural, and habit memory are relatively spared until advanced dementia (de Vreese, Neri, Fioravanti, Belloi, & Zanetti, 2001; Salmon, Heindel, & Butters, 1992). In Parkinson's disease, the neural structures supporting nondeclarative and

working memory are more vulnerable early, whereas those supporting declarative memory are relatively spared. *Clinicians can use early spared systems to help individuals compensate for disease effects and inform caregivers about how to reduce demands on impaired systems.*

The discovery of the differential vulnerability of the brain's representation systems to AD motivated investigations of the potential of procedural learning treatments and conditioning for improving function and quality of

life for AD patients. A considerable literature now exists documenting improved skill learning in AD patients through programs that capitalized on spared procedural memory systems and conditioning (de Werd, Boelen, Rikkert, & Kessels, 2013; Deweer et al., 1994; Deweer, Pillon, Michon, & Dubois, 1993; Dick, Hsieh, Bricker, & Dick-Muehlke, 2003; Dick et al., 1996; Grober, Ausubel, Sliwinski, & Gordon, 1992; Keane, Gabrieli, Fennema, Growdon, & Corkin, 1991; van Halteren-van Tilborg, Scherder, Hulstijn, 2007; Verfaellie, Keane, & Johnson, 2000). For individuals with MCI, who have not evolved to dementia, strengthening their knowledge and skills (cognitive reserve) is the primary goal. Their ability to learn new factual information will be greatly influenced by the degree of their episodic memory impairment. Early on, when episodic memory is minimally affected, new fact learning is easier. As the disease progresses, more emphasis can be placed on using the spared nondeclarative memory/learning systems than on the more impaired declarative systems. Regardless of stage, however, consistent use of retained skills and knowledge helps maintain them.

Cognitive Reserve

The term “*cognitive reserve*” refers to the mind’s ability to cope with brain damage. One cannot assume that people with similar amounts of brain damage, by virtue of disease or injury, have similar cognitive abilities. This fact is apparent in individuals with AD. Research has shown that some individuals with extensive brain pathology display few, if any, cognitive deficits in life (Katzman et al., 1988). In fact, approximately 25% of individuals with AD pathology whose brains undergo postmortem examination were symptom free in life (Ince, 2001). Why the discrepancy?

Scientists theorize that some individuals may have had more neurons to begin with; others suggest that some internal or external

mechanism prevents the extensive neuronal loss typical of the disease. Yet, others suggest that a richer network of interneuronal connections, as a result of education and life experiences, have had a neuroprotective effect. All of these theories are true.

Katzman and colleagues (1988) found an association between brain size and degree of AD symptomatology. Patients who had few symptoms and extensive pathology had higher brain weights and more neurons. More recently, Perneckzy et al. (2012) reported that clinical and epidemiologic studies suggest that AD patients who have larger head sizes have better cognitive performance than those with smaller head circumferences, even though the degree of neuropathology is the same.

One “external mechanism” known to influence susceptibility to the effects of AD is amount of education. Individuals with greater education have a reduced risk of developing AD (Anttila et al., 2002; Evans et al., 1993; Evans et al., 1997; Letenneur, Commenges, Dartigues, & Barberger-Gateau, 1994; Stern et al., 1994; White et al., 1994; Zhang et al., 1990). Furthermore, slower decline in cognitive function has been reported in people with more education (Albert et al., 1995; Butler, Ashford, & Snowden, 1996; Chodosh, Reuben, Albert, & Seeman, 2002; Christensen et al., 1997; Colsher & Wallace, 1991; Farmer, Kittner, Rae, Bartko, & Regier, 1995; Lyketsos, Chen, & Anthony, 1999; Sando et al., 2008; Snowden, Ostwald, & Kane, 1989). Similarly, people with more education and cognitively challenging careers have better cognitive reserves that reduce risk of dementia (Cheng, 2016; Katzman, 1993; Stern, 2002; Valenzuela & Sachdev, 2005).

Education provides cognitive stimulation and cognitive stimulation results in synaptogenesis and a richer network of interconnected neurons, or brain reserve. Cognitive reserve is related to brain reserve (physical characteristics of brain, e.g., more neurons). Brain reserve can be characterized in any number of ways including brain size, number of neurons, synapse count, and degree of dendritic branching.

- Downar, J., Crawley, A. P., Mikulis, D. J., & Davis, K. D. (2000). A multimodal cortical network for the detection of changes in the sensory environment. *Nature Neuroscience*, 3, 277–283.
- Dronkers, N. F., Redfern, B. B., & Knight, R. T. (2000). The neural architecture of language disorders. In M. S. Gazzaniga (Ed.), *The new cognitive neurosciences* (pp. 949–958). Cambridge, MA: MIT Press.
- Eichenbaum, H. (2002). *The cognitive neuroscience of memory*. Cambridge, UK: Oxford University Press.
- Eichenbaum, H. (2012). *The cognitive neuroscience of memory* (2nd ed.). New York, NY: Oxford University Press.
- Emery, V. O. B. (2003). “Retrophylogenesis” of memory in dementia of the Alzheimer type. In V. O. B. Emery & T. E. Oxman (Eds.), *Dementia: Presentation, differential diagnosis, and nosology* (pp. 177–236). Baltimore, MD: Johns Hopkins University Press.
- Farah, M. J., & Grossman, M. (1997). Semantic memory impairments. In T. E. Feinberg & M. J. Farah (Eds.), *Behavioral neurology and neuropsychology* (pp. 473–477). New York, NY: McGraw-Hill.
- Fedorenko, E., Nieto-Castanon, A., & Kanwisher, N. (2011). Lexical and syntactic representations in the brain: An fMRI investigation with multivoxel pattern analyses. *Neuropsychologia*, 50, 499–513.
- Fodor, J. (1975). *The language of thought hypothesis*. New York, NY: Crowell Press.
- Franks, J. J., & Bransford, J. D. (1974). Memory for syntactic form as a function of semantic context. *Journal of Experimental Psychology*, 103, 1037–1039.
- Gaffan, D. (1974). Recognition impaired and association intact in the memory of monkeys after transection of the fornix. *Journal of Comparative and Physiological Psychology*, 86, 1100–1109.
- Harrell, M., Parente, F., Bellingrath, E. G., & Lisicia, K. A. (1992). *Cognitive rehabilitation of memory: A practical guide*. Gaithersburg, MD: Aspen.
- Hirsh, R. (1974). The hippocampus and contextual retrieval from memory: A theory. *Behavioral Biology*, 12, 421–444.
- Huth, A. G., de Heer, W. A., Griffiths, T. L., Theunissen, F. E., & Gallant, J. L. (2016). Natural speech reveals the semantic maps that tile human cerebral cortex. *Nature*, 532, 453–459.
- Hyman, S. E. (1998). A new image of fear and emotion. *Nature*, 393, 417–418.
- Indefrey, P., & Cutler, A. (2004). Prelexical and lexical processing in listening. In M. S. Gazzaniga (Ed.), *The cognitive neurosciences* (pp. 759–774). Cambridge, MA: MIT Press.
- Iversen, S., Kupfermann, I., & Kandel, E. R. (2000). Emotional states and feelings. In E. R. Kandel, J. Schwartz, & T. M. Jessell (Eds.), *Principles of neural science* (pp. 982–997). New York, NY: McGraw-Hill.
- James, W. (1890). *The principles of psychology*. New York, NY: H. Holt & Company.
- Karpicke, J. D., & Lehman, M. (2013). Human memory. In D. S. Dunn (Ed.), *Oxford bibliographies online: Psychology*. New York, NY: Oxford University Press.
- Kintsch, W., & Glass, G. (1974). Effects of propositional structure upon sentence recall. In W. Kintsch (Ed.), *The representation of meaning in memory* (pp. 140–151). Hillsdale, NJ: Lawrence Erlbaum Associates.
- Knowlton, B. J., Mangels, J. A., & Squire, L. R. (1996). A neostriatal habit learning system in humans. *Science*, 273, 1399–1402.
- Luria, A. (1973). *The working brain*. New York, NY: Basic Books.
- Martin, A., & Chao, L. L. (2001). Semantic memory and the brain: Structure and processes. *Current Opinion in Neurobiology*, 11, 194–201.
- Miller, G. A. (1956). The magical number seven, plus or minus two: Some limits on our capacity for processing information. *Psychological Review*, 63, 81–97.
- Mishkin, M., Malamut, B., & Bachevalier, J. (1984). Memories and habits: Two neural systems. In G. Lynch, J. McGaugh, & N. Weinberger (Eds.), *Neurobiology of learning and memory* (pp. 65–77). New York, NY: Guilford Press.
- Mishkin, M., Siegle, B., Saunders, R. C., & Malamut, B. J. (1982). An animal model of global amnesia. In S. Corkin, K. L. Davis, J. H. Growdon, E. Usdin, & R. J. Wurtman (Eds.), *Toward a treatment of Alzheimer’s disease* (pp. 235–247). New York, NY: Raven Press.
- Nadel, L., & Hardt, O. (2011). Update on memory systems and processes. *Neuropsychopharmacology*, 36, 251–273.
- Nadel, L., & O’Keefe, J. (1974). The hippocampus in pieces and patches: An essay on modes of explanation in physiological psychology. In R. Bellairs & E. G. Gray (Eds.), *Essays on the nervous system. A festschrift for JZ Young*. Oxford, UK: Clarendon Press.
- Ogmen, H., & Herzog, M. H. (2016). A new conceptualization of human visual sensory memory. *Frontiers in Psychology*, 7, 830.
- Quillian, M. R. (1966). *Semantic memory* (Unpublished doctoral dissertation). Carnegie Institute of Technology, Pittsburgh, PA. Reprinted in part in M. Minsky (Ed.). (1968). *Semantic information processing*. Cambridge, MA: MIT Press.
- Rochon, E., Waters, G. S., & Caplan, D. (1994). Sentence comprehension in patients with Alzheimer’s disease. *Brain and Language*, 46, 329–349.
- Sachs, J. S. (1967). Recognition memory for syntactic and semantic aspects of connected discourse. *Perception and Psychophysics*, 2, 437–444.
- Schacter, D. L. (1985). Multiple forms of memory in humans and animals. In N. Weingerger, J. McGaugh, & G. Lynch (Eds.), *Memory systems of the brain: Animal and human cognitive processes* (pp. 351–379). New York, NY: Guilford Press.
- Schacter, D. L., Wagner, A. D., & Buckner, R. L. (2000). Memory systems of 1999. In E. Tulving & F. I. M. Craik (Eds.), *Oxford handbook of memory* (pp. 627–643). New York, NY: Oxford University Press.
- Smith, E. E., & Jonides, J. (1999). Storage and executive processes in the frontal lobes. *Science*, 283, 1657–1661.

CLINICAL MANAGEMENT GUIDE

Assessments and Interventions for Cognitive-Communication Disorders of Dementia





II

Assessment

Introduction

Assessment of cognitive function is critical to the early identification of individuals with mild cognitive impairment (MCI) or dementia. For individuals with MCI, early identification has profound benefits because lifestyle changes, cognitive stimulation, and drug therapy can prevent or slow evolution to dementia. Comprehensive evaluation of cognitive and linguistic functions is needed to correctly diagnose and treat those affected and for family counseling. In this section three major topics are addressed:

Assessment procedures that produce valid and reliable data

Tests for diagnosing MCI and dementia

Differentiating the types of dementia

Assessment Procedures that Produce Valid and Reliable Data

The diagnosis of MCI or dementia is made on the basis of history, performance on neuropsychological tests, perceptions of patients and families, and biomarker data from laboratory and imaging results. Currently, however, biomarker data are generally unavailable and results of cognitive-linguistic assessment are the primary basis primarily used for making a diagnosis. Therefore, clinicians should use assessments for which there are normative data

on the performance of healthy individuals of a similar age and, if possible, individuals with MCI or dementia. Additionally, clinicians must control for sensory loss and other age-related conditions that can affect cognitive functioning and lead to inaccurate conclusions about mental status and functional abilities.

Prior to Testing

Take a Case History

- What were the presenting symptoms?
- When did they develop?
- Are the symptoms variable? Variability in mental status is characteristic of individuals with Lewy body dementia.
- Is there evidence of more than one neurologic problem? Individuals with Alzheimer's disease (AD) frequently have vascular disease and those with vascular disease often have AD.
- Does the client have other medical problems?
- Does the client have a history of depression?
- What, if any, drugs does the client take?
- What, if any, laboratory tests or neuroimaging has the client had? And, what are the results?
- If the client has a diagnosis of dementia, what is the presumptive cause?
- What is the severity of dementia? Clinicians should be familiar with the commonly used severity rating scales and the scores that correspond to mild, moderate, and severe dementia (Table I-1).

Table I-1. Three Commonly Used Measures of Dementia Severity and Scores/Ratings that Correspond to Mild, Moderate, and Severe Dementia

Measure	Mild Dementia	Moderate-Moderately Severe Dementia	Severe Dementia
Global Deterioration Scale (GDS; Reisberg, Ferris, de Leon, & Crook, 1982): The course of dementia is defined in seven stages that have specific observational criteria. GDS stage 1 represents “normal” aging without evidence of cognitive decline. GDS stage 7 represents “late dementia” with very severe cognitive decline.	3 or 4	5 or 6	7
Clinical Dementia Rating Scale (CDR; Hughes et al., 1982): The CDR provides a rating of global cognitive function based on clinical information about memory, orientation, judgment, problem solving, community affairs, home and hobbies, and personal care. Level of impairment is rated as none (0), questionable (0.5), mild (1), moderate (2), or severe (3).	CDR 1	CDR 2	CDR 3
Dementia Rating Scale (DRS; Mattis, 1976): The DRS contains items that evaluate five cognitive functions: attention, initiation and perseveration, construction, conceptualization, and memory. A maximum of 144 points can be awarded and normal elders obtain scores of 140 or more.	120–130	90–119	<90

- Review the patient’s medical history for information about sensory impairment (i.e., macular degeneration, moderate to severe hearing loss) and other conditions that can alter cognitive function (i.e., depression, drug effects).

Arrange for a Good Test Environment

Testing should be conducted in a quiet room with adequate lighting. Illuminate test materials in a way that prevents shadows and remember that elders need two to three times more illumination than young adults. Glare can impair an elder’s vision. Avoid sitting with your back to a bright light or window that makes your facial features hard to perceive. Test stimuli should be printed in a font size that is readily perceptible. Black print on a white background is the easiest for elders to see. Avoid

putting words in all caps as they are harder to comprehend.

Check Vision

Visual acuity diminishes with age and many elders need glasses to read. If the patient’s vision status is unknown, a standard eye chart can be used to screen for a visual deficit or the patient can be asked to read simple words in a print size *smaller* than the test stimuli. If the patient can read text in the smaller print, you can be assured that the patient has adequate visual acuity to see the printed test materials.

Check Hearing

Hearing loss is more common with age (Cruickshanks, 2009; NIDCD, 2017). Indeed, age is the strongest predictor of hearing loss and those with the greatest amount of loss are typically

older than 60 years. Men are twice as likely as women to have hearing loss (Hoffman, Dobie, Losonczy, Themann, & Flamme, 2017). Nearly one-quarter of adults aged 65 to 74 and 50% of those who are 75 and older have disabling hearing loss.

If the patient has hearing aids, have the patient wear them during testing. If a full audiometric evaluation cannot be obtained, a simple speech discrimination test can be given to ensure that the examinee can hear the clinician's voice in the test environment. Have the client repeat words that sound similar (like "cake" and "take") to determine if they can discriminate subtle differences. Use the same intonation and loudness level when presenting the stimulus word pairs. An example of this type of speech discrimination task can be found in the Arizona Battery for Cognitive-Communication Disorders (ABCD-2) (Bayles & Tomoeda, 2019). An error rate of 30% or greater indicates that the patient's hearing will likely impact test performance.

Check Literacy

Check for literacy by having the examinee read two or three simple sentences. Generally, even individuals with moderately severe dementia are able to read aloud if they were literate prior to the onset of dementia.

Take Steps to Reduce Test-Taking Anxiety

Before testing, visit with the examinee and describe what will occur during the session. Position score sheets so the examinee cannot see you record responses. When examinees ask about their performance, tell them the testing is going well. During testing, do not tell examinees if their responses are correct.

Some individuals, particularly those with dementia, become anxious about where their spouse or family member is. Give assurance that the caregiver is nearby. If an examinee will not participate in the evaluation without the caregiver being present, allow the caregiver to be present but refrain from giving cues.

Be Alert to Depression

Depression is common in older adults and can negatively affect test performance. In fact, its effects can mimic dementia. Historically, the term "pseudodementia" was used to designate a dementia-like performance in a cognitively intact but depressed individual (Kiloh, 1961). However, in recent years, the term has fallen out of favor (Alexopoulos, 2003; Dobie, 2002; Emery & Oxman, 2003) because research has shown that depression is frequently an early sign of a dementing disease (Alexopoulos, Young, & Meyers, 1993; Kral & Emery, 1989; Saczynski et al., 2010).

Individuals who are depressed generally convey a sense of distress. Often, they make self-deprecatory comments. Some are uninterested in the testing and its outcome. A subsequent part of this section is devoted to differentiating mild AD from delirium and depression. Table I-2 contains brief descriptions of tests that can be used to screen for depression in adults.

Be Alert to Drug Effects on Performance

Most elders and many middle-aged individuals at risk for dementia take several medications to manage age-associated chronic disease (Lamy, 1986). The potential for adverse drug interactions rises with advancing age because of age-related physiologic change, greater occurrence of comorbid diseases, and an increase in the number of medications prescribed (Hines & Murphy, 2011; Seymour & Routledge, 1998). Sloan (1983) reported that the potential for drug interaction is 5.6% when patients take two drugs and increases to 100% when patients take eight or more drugs. Similarly, Larson, Kukull, Buchner, and Reifler (1987) found that drug reactions that impair cognitive function increase as the number of prescription drugs increases. In a review of 16 studies that included 1,551 patients, Weytingh, Bossuyt, and van Crevel (1995) found that drugs were a frequent cause of reversible dementia.

Table I-2. Screening Tests for Depression

Name of Measure	Reference	Description
Hamilton Rating Scale for Depression (HRS-D)	Hamilton (1967, 1970)	The HRS-D is one of the first-developed and best-known interview-based rating scales for depression. It is a 17-item inventory of symptoms that are rated for severity by an experienced clinician, based on an interview and other available data.
Beck Depression Inventory (BDI)	Beck, Ward, Mendelson, Mock, & Erbaugh (1961)	The BDI is a 21-item inventory of depressive symptoms and attitudes that are rated from 0 to 3 in terms of intensity. The BDI is commonly used as a self-administered measure, although it was designed for administration by trained interviewers.
Zung Self-rating Depression Scales (SDS)	Zung (1965)	The SDS comprises 20 items that evaluate four areas of disturbance: pervasive psychic, physiologic, psychomotor, and psychologic. The patient rates the applicability, within the past week, of each item according to the following terms: "none or a little of the time," "some of the time," "good part of the time," and "most or all of the time."
Zung Depression Status Inventory (DSI)	Zung (1972)	The 20 items of the DSI correspond to the SDS; however, the interviewer rates the severity of symptoms or signs on a four-point scale from none to severe based on the results of a clinical interview.
Dementia Mood Assessment Scale	Sunderland et al. (1988)	This two-part instrument is designed to measure the severity of mood disturbance of demented patients based on direct observation and a semistructured interview by health professionals. The first 17 items evaluate mood and are scaled from 0 (within normal limits) to 6 (most severe). The remaining seven items measure the patient's functional capacities.
Cornell Scale for Depression in Dementia	Alexopoulos, Abrams, Young, & Shamoian (1988)	The Cornell Scale is a 19-item clinician-administered instrument that uses information obtained from interviews with the patient and a member of the nursing staff. This instrument was specifically designed for measuring depression in demented patients.

Orange (2001) listed classes of drugs that commonly interfere with speech, language, and cognition in persons with dementia. They include:

Sedatives

Antidepressants

Anxiolytics (antianxiety drugs)

Antipsychotics

Anticoagulants

Antihypertensives

Narcotic-based analgesics

Massey (2005) cautioned that long-term use of benzodiazepines can interfere with the ability to learn, and long-term use of anticholinergic medications (Artane, Cogentin, Atropine) and

antihistamines (Benadryl, Dimetapp, Chlortrimeton) can contribute to confusion. Mental status changes also occur with medications for incontinence (Detrol, Ditropan), motility (Levsin, Bentyl), and pain.

Know the Criteria for Diagnosing MCI and Dementia

The criteria for diagnosing MCI and dementia provide a guideline for the assessment.

Criteria for diagnosing MCI (Albert et al., 2011) are as follows:

1. **Concern regarding a change in cognition.** Concern can be expressed by the person

or an informant who knows the individual well or a skilled clinician.

2. **Impairment in one or more cognitive domains.** Evidence is needed of lower performance in one or more cognitive domains that is greater than would be expected for the patient's age and education. Remember that change can occur in a variety of cognitive domains, including language, attention, visuospatial skills, memory, and executive function. Scores on tests of those with MCI are typically 1 to 1.5 standard deviations (SD) below the mean for age and education.
3. **Preservation of independence in basic functional abilities.**
4. **No dementia.**

Take Into Account Degree of Intelligence and Education in Evaluating Test Performance

The challenge of identifying MCI or mild dementia is that intelligence and degree of education vary considerably in the healthy population. Without taking into account intelligence and education, you can mistakenly conclude that a low-average or average performance is normal in a highly intelligent and educated individual when, in fact, the individual has MCI. Similarly, you can mistakenly conclude that a below average performance of a person, who has below average intelligence, is evidence of impairment. To cope with these challenges, the authors of the diagnostic clinical criteria for MCI established the following performance cutoffs.

A performance of 1 to 2 SD below the mean of healthy elders with similar education is considered indicative of cognitive impairment (Albert et al., 2011).

Clearly, to make this comparison, you need to administer tests for which there are normative data for healthy adults.

Criteria for diagnosing dementia (American Psychiatric Association, 2013) are as follows:

1. **Individual exhibits significant cognitive decline from a previous level of performance.**
2. **The cognitive deficits are sufficient to interfere with independence in everyday activities.** At a minimum, assistance should be required with complex instrumental activities of daily living, such as paying bills or managing medications.
3. **The cognitive deficits do not occur exclusively in the context of delirium.**
4. **The cognitive deficits are not better explained by another mental disorder.**

The National Institutes of Health–Alzheimer's Disease and Related Disorders Association (NIH-ADRDA) working group acknowledges that specifying the definitive points at which individuals transition from MCI to dementia and mild to moderate dementia is difficult. Efforts to refine the criteria for characterizing the various stages of dementing diseases (asymptomatic preclinical, symptomatic predementia, and clinically apparent dementia) are ongoing (Albert et al., 2011; McKhann et al., 2011; Sperling et al., 2011). Thus, some degree of clinical judgment is involved. However, to improve decision making, use tests for which there are normative data on the performance of healthy adults, and, if possible, measures that also have data on the performance of individuals with mild and moderate dementia (for whom etiology is specified).

Severity of Cognitive Impairment Affects Test Selection

We have found, and others have confirmed (Locascio, Growdon, & Corkin, 1995), that tests suitable for early detection of cognitive impairment are unsuitable for documenting abilities in severely demented individuals. If a test is sufficiently cognitively challenging for identifying individuals with MCI, it is usually too difficult for individuals with moderate dementia and *floor effects* emerge. Similarly, tests designed to characterize cognitive-communicative functioning in the later stages of dementia are generally too easy for individuals in the mild stage, and the result is a *ceiling effect*. It is the